In fact, PRC2-deficient cancers such as high-grade malignant peripheral nerve sheath tumour have been shown to benefit from DNMTi treatment the most because of their enhanced viral mimicry resulting from protein kinase R (PKR)-dependent dsRNA sensor activity [78], and combined treatment targeting both DNMTs and PRC2 was exactly indicated to augment antitumor immunity [75]. The gene discussed is EIF2AK2; the disease is cancer.